FY2026 EPS Estimates for TSE:MDP Boosted by Leede Financial

Medexus Pharmaceuticals Inc. (TSE:MDP) – Equities researchers at Leede Financial upped their FY2026 EPS estimates for Medexus Pharmaceuticals in a report issued on Wednesday, January 22nd. Leede Financial analyst D. Loe now anticipates that the company will post earnings per share of $0.29 for the year, up from their prior estimate of $0.22. Leede Financial has a “Strong-Buy” rating on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share.

MDP has been the topic of several other reports. Ventum Cap Mkts raised Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Raymond James upgraded shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price for the company in a research report on Wednesday, January 8th. Stifel Nicolaus upped their target price on shares of Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research report on Tuesday, January 14th. Finally, Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. One analyst has rated the stock with a buy rating and five have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Strong Buy” and a consensus target price of C$5.58.

Medexus Pharmaceuticals Stock Performance

Medexus Pharmaceuticals stock opened at C$4.92 on Friday. The business’s 50-day simple moving average is C$3.25 and its 200-day simple moving average is C$2.72. The firm has a market capitalization of C$120.69 million, a PE ratio of 98.40 and a beta of 1.96. Medexus Pharmaceuticals has a 52 week low of C$1.47 and a 52 week high of C$5.56.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.